Iran Conflict Medicine Shortage in India : The ongoing conflict in Iran is now impacting India’s pharmaceutical sector, causing concerns over the availability of essential drugs. According to industry sources, the situation has triggered supply chain disruptions that could lead to rising prices and potential shortages of widely used medicines. The Iran Conflict Medicine Shortage in India is emerging as a serious issue that requires immediate government intervention.
Impact on Drug Availability
Supplies of raw materials for commonly used drugs, including Paracetamol, Metformin, Amoxicillin, and Azithromycin, have been affected due to delays in international shipments. The Federation of Pharma Entrepreneurs (FOPE) has sent an urgent communication to the central government warning that without prompt action, India could face significant shortages.
Wholesale prices have already seen a surge of 10–15%, with the cost increase expected to be passed on to patients. The Iran Conflict Medicine Shortage in India is being closely monitored at both the factory and wholesale levels.
Sharp Rise in Input Costs
FOPE reports that prices of Active Pharmaceutical Ingredients (APIs) have risen by 20–60% in just over a week, while chemical solvents, intermediates, and packaging materials have also seen sharp price hikes. These cost increases have turned many existing production contracts into loss-making arrangements, forcing smaller pharmaceutical units to slow or halt production.
Also read : New Aviation Rules 2026: 60% Free Seats and Assured Group Seating for Families
Such disruptions contribute directly to the Iran Conflict Medicine Shortage in India, as manufacturers struggle to maintain output despite rising costs and irregular supplies.
Supply Chain Disruptions Linked to Iran Conflict
India sources over 70% of its APIs from China, and transport routes passing through the Strait of Hormuz, Red Sea, and Suez Canal have been affected by the Iran conflict. Ships are now taking longer, costlier routes, increasing shipping times from 20 days to 45–50 days and raising shipping costs three to five times. The resulting Iran Conflict Medicine Shortage in India highlights the vulnerability of the global pharmaceutical supply chain.
Just-In-Time Inventory Model Adds to Risks
Indian pharmaceutical companies typically maintain minimal stock under a “just-in-time” inventory model. While efficient under normal circumstances, this approach has amplified the effects of the current disruption, increasing the risk of medicine shortages. If delays continue, the Iran Conflict Medicine Shortage in India could affect essential medicines for diabetes, fever, respiratory issues, and other common conditions.
Industry Seeks Immediate Government Action
FOPE has requested the National Pharmaceutical Pricing Authority (NPPA) to allow price adjustments under extraordinary circumstances, citing sharp increases in input costs. While long-term initiatives like the Production Linked Incentive (PLI) scheme aim to boost domestic API production, immediate measures are needed to mitigate the Iran Conflict Medicine Shortage in India.
Potential Price Increases for Patients
If the crisis persists, wholesale and retail medicine prices could rise by 10–15%, increasing the cost burden for patients who rely on daily medications. Medicines priced at Rs 50 could surge to Rs 60–65, directly impacting individuals with chronic illnesses. The Iran Conflict Medicine Shortage in India underscores the urgency of proactive steps to secure essential drug supplies and prevent widespread shortages.